BioVie A New Approach to Targeting Parkinson’s

While current treatments for Parkinson’s primarily focus on managing symptoms by replacing dopamine, a new therapy in development aims to address the underlying drivers of the condition. BioVie Inc. is currently advancing an oral drug called bezisterim (NE3107) that could represent the first significant shift in how we treat the condition in over fifty years. Targeting the Root Causes The scientific theory behind BioVie's approach is that the symptoms of the condition only emerge when two factors collide: low dopamine levels and chronic inflammation that leads to insulin resistance in the brain. Bezisterim is a small-molecule drug designed to cross the blood-brain barrier and block specific inflammatory signals (TNF-alpha). By reducing this neuroinflammation and improving how brain cells use energy, the therapy aims to protect neurons and potentially slow the progression of the condition, rather than just masking the symptoms. Encouraging Trial Results The company has already seen promising results in its clinical programmes: Enhanced Motor Control: In a Phase 2 study, people who took bezisterim alongside their standard levodopa treatment saw better motor control and a significant reduction in "morning off" symptoms—the period when medication wears off before the next dose. Stand-alone Potential: Younger people (under 70) in the trials showed even more pronounced improvements, suggesting the drug might be particularly effective when used earlier in the journey. Non-Motor Benefits: Data also indicated improvements in common non-motor issues, such as sleep quality and fatigue, which are often just as debilitating as movement challenges. The Path Forward: SUNRISE-PD BioVie has recently completed enrollment for its SUNRISE-PD trial, a Phase 2 study involving 60 people who have been recently diagnosed and have not yet started levodopa. The goal is to see if bezisterim can work as a stand-alone therapy to delay the need for dopamine-replacement drugs and protect the brain’s remaining dopamine-producing cells. Because this trial uses a "decentralised" design, participants have been able to complete many of their visits from home. This approach makes research more accessible to those with limited mobility or those living far from major medical centres. What’s Next? The results from the SUNRISE-PD trial are expected in mid-2026. If the data is positive, it could pave the way for a completely new class of treatment—one that focuses on keeping brain cells healthy for longer. Beyond Parkinson’s, the drug’s ability to tackle brain inflammation is also being studied for its potential in treating Alzheimer’s and Long COVID, highlighting the growing consensus that inflammation is a key player in many neurological conditions.